By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk will target launches of its mega popular obesity shot Wegovy in markets where it already …
INDIANAPOLIS, IN – Pharmaceutical giant Eli Lilly announced the availability of its new obesity treatment, Zepbound, in U.S. pharmacies. The drug, priced at $550 monthly …
By Bhanvi Satija and Amruta Khandekar (Reuters) – Retail flows into Eli Lilly spiked to a more than two-year high in November, as small investors …
By Maggie Fick and Bhanvi Satija (Reuters) – Novo Nordisk and Eli Lilly both expect juggernaut sales for their diabetes and weight-loss drugs to extend …
(Reuters) – Eli Lilly and Co said on Thursday it will acquire all the shares of Sigilon Therapeutics that it did not own to gain …
By Deena Beasley (Reuters) -Eli Lilly on Monday said a mid-stage trial of its next-generation obesity drug candidate “triple G” showed that it led to …
By Deena Beasley (Reuters) -In a mid-stage trial, the highest dose of Eli Lilly’s experimental pill orforglipron led to 14.7% weight loss after 36 weeks …
(Reuters) – Eli Lilly and Co said on Monday it will invest an additional $1.6 billion at its two new manufacturing sites in Indiana, United …
(Removes reference to Ricks’ comment on apology from Lilly in paragraph 3) (Reuters) -Eli Lilly & Co Chief Executive Officer Dave Ricks said on Wednesday …
By Natalie Grover LONDON (Reuters) – The results of a key Alzheimer’s drug trial on Wednesday have reignited decades-old hopes that targeting a particular protein …